transient receptor potential cation channel subfamily M member 6Genealiases: CHAK2 · HMGX · HOMG · HOMG1 · HSH
Q-omics provides the consensus-scored TRPM6 profile across patient tissues and cancer cell-line models. TRPM6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRPM6 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TRPM6 RNA expression shows 17,447 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where TRPM6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM6 survival associations across molecular data types. TRPM6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM6 RNA expression–survival associations across cancer types. High TRPM6 expression shows unfavorable associations in UVM, ACC, MESO and SKCM, but favorable associations in PAAD and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRPM6 RNA expression.
This table summarizes TRPM6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRPM6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM6 shows lower tumor expression in COAD, KIRC, KIRP, THCA, LUAD and BRCA. The COAD box plot shows higher TRPM6 RNA expression in normal versus tumor tissue (log2 FC = −3.852, t-test p < 0.001).
This table shows molecular features associated with TRPM6 in patient tissues and cancer cell lines. In patient samples, TRPM6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPM6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
